CLLS Stock Summary and Trading Ideas (Cellectis S.A. - American Depositary Shares | NASDAQ:CLLS)

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Cellectis S.A. - American Depositary Shares trades on the NASDAQ stock market under the symbol CLLS.

As of December 16, 2025, CLLS stock price declined to $4.06 with 137,815 million shares trading.

CLLS has a beta of 0.71, meaning it tends to be less sensitive to market movements. CLLS has a correlation of 0.02 to the broad based SPY ETF.

CLLS has a market cap of $407.18 million. This is considered a Small Cap stock.

Last quarter Cellectis S.A. - American Depositary Shares reported $37 million in Revenue and $.02 earnings per share. This beat revenue expectation by $29 million and exceeded earnings estimates by $.12.

In the last 3 years, CLLS traded as high as $5.48 and as low as $.96.

CLLS has outperformed the market in the last year with a return of +134.7%, while the SPY ETF gained +13.1%. In the last 3 month period, CLLS beat the market returning +28.5%, while SPY returned +3.1%. However, in the most recent 2 weeks CLLS has underperformed the stock market by returning -13.8%, while SPY returned -0.4%.

CLLS support price is $4.47 and resistance is $5.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CLLS shares will trade within this expected range on the day.